Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry.
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ diagnosis
Female
Gene Expression Profiling
Humans
Immunohistochemistry
Ki-67 Antigen
/ genetics
Neoplasm Recurrence, Local
/ pathology
Prognosis
RNA
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Reverse Transcriptase Polymerase Chain Reaction
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 03 2022
07 03 2022
Historique:
received:
01
07
2021
accepted:
16
02
2022
entrez:
8
3
2022
pubmed:
9
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expression of 21 specific genes from tumor tissue, including Ki67. The primary aim of this study was to assess the agreement between Ki67
Identifiants
pubmed: 35256657
doi: 10.1038/s41598-022-07593-7
pii: 10.1038/s41598-022-07593-7
pmc: PMC8901910
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
Receptors, Estrogen
0
RNA
63231-63-0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3617Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
Breast Care (Basel). 2017 May;12(2):102-107
pubmed: 28559767
Mod Pathol. 2016 Apr;29(4):318-29
pubmed: 26916072
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
Acta Oncol. 2015 Jul;54(7):1040-8
pubmed: 25959664
Mod Pathol. 2015 Jun;28(6):778-86
pubmed: 25698062
Eur J Cancer. 2013 Jul;49(11):2469-75
pubmed: 23611660
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Eur J Cancer. 2017 Oct;84:219-227
pubmed: 28829990
Clin Cancer Res. 1996 Jan;2(1):147-54
pubmed: 9816101
J Oncol Pract. 2017 Nov;13(11):763-766
pubmed: 28696818
Histopathology. 2020 Apr;76(5):650-660
pubmed: 31846096
Histopathology. 2012 Dec;61(6):1134-44
pubmed: 22963617
Oncologist. 2015 Apr;20(4):344-50
pubmed: 25795632
Acta Oncol. 2018 Jan;57(1):58-66
pubmed: 29164972
Ann Oncol. 2015 Sep;26 Suppl 5:v8-30
pubmed: 26314782
J Clin Oncol. 2017 Apr 1;35(10):1061-1069
pubmed: 28045625
Bull Cancer. 2014 Jul-Aug;101(7-8):681-9
pubmed: 25091650
J Clin Oncol. 2016 Jul 10;34(20):2341-9
pubmed: 26926676
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
J Pathol. 2002 Nov;198(3):292-9
pubmed: 12375261
N Engl J Med. 2015 Nov 19;373(21):2005-14
pubmed: 26412349
J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
pubmed: 17228000
Br J Cancer. 2007 May 21;96(10):1504-13
pubmed: 17453008
Cancer. 2003 Mar 1;97(5):1321-31
pubmed: 12599241
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Breast Cancer Res Treat. 2016 Sep;159(2):257-63
pubmed: 27558625
CA Cancer J Clin. 2020 Jul;70(4):313
pubmed: 32767693
Br J Cancer. 2013 Jun 11;108(11):2250-8
pubmed: 23695023
Breast. 2019 Apr;44:39-45
pubmed: 30634106
Mol Oncol. 2015 May;9(5):960-6
pubmed: 25458054
Eur J Cancer. 2017 Apr;75:284-298
pubmed: 28259011
Cancer Res. 2003 Oct 1;63(19):6523-31
pubmed: 14559846
Oncologist. 2015 Aug;20(8):873-9
pubmed: 26112003
Eur J Cancer. 2015 Aug;51(12):1481-9
pubmed: 26074397
Neoplasia. 2019 Oct;21(10):1015-1035
pubmed: 31476594
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Eur J Surg Oncol. 2017 May;43(5):921-930
pubmed: 28087099
Eur J Cancer. 2014 Nov;50(16):2763-70
pubmed: 25240289
Breast Cancer Res Treat. 2017 Jun;163(2):303-310
pubmed: 28243896
Breast. 2008 Aug;17(4):323-34
pubmed: 18455396
J Natl Cancer Inst. 2021 Jul 1;113(7):808-819
pubmed: 33369635